BACKGROUND AND OBJECTIVES: Tissue advanced glycation end products (AGE) accumulation is a measure of cumulative metabolic stress. Assessment of tissue AGE by skin autofluorescence (SAF) correlates well with cardiovascular (CV) outcomes in diabetic, transplant, and dialysis patients, and may be a useful marker of CV risk in earlier stages of chronic kidney disease (CKD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: 1707 patients with estimated GFR 59 to 30 ml/min per 1.73 m(2) were recruited from primary care practices for the Renal Risk In Derby (RRID) study. Detailed medical history was obtained, and each participant underwent clinical assessment as well as urine and serum biochemistry tests. SAF was assessed (mean of three readings) as a measure of skin AGE deposition using a cutaneous AF device (AGE Reader™, DiagnOptics, Groningen, The Netherlands). RESULTS: Univariate analysis revealed significant correlations between AF readings and several potential risk factors for cardiovascular disease (CVD) and progression of CKD. SAF readings (arbitrary units) were also significantly higher among males (2.8 ± 0.7 versus 2.7 ± 0.6), diabetics (3.0 ± 0.7 versus 2.7 ± 0.6), patients with evidence of self-reported CVD (2.9 ± 0.7 versus 2.7 ± 0.6), and those with no formal educational qualifications (2.8 ± 0.6 versus 2.6 ± 0.6; P < 0.01 for all). Multivariable linear regression analysis identified hemoglobin, diabetes, age, and eGFR as the most significant independent determinants of higher SAF (standardized coefficients -0.16, 0.13, 0.12, and -0.10, respectively; R(2) = 0.17 for equation). CONCLUSION: Increased SAF is independently associated with multiple CV and renal risk factors in CKD 3. Long-term follow-up will assess the value of SAF as a predictor of CV and renal risk in this population.
BACKGROUND AND OBJECTIVES: Tissue advanced glycation end products (AGE) accumulation is a measure of cumulative metabolic stress. Assessment of tissue AGE by skin autofluorescence (SAF) correlates well with cardiovascular (CV) outcomes in diabetic, transplant, and dialysis patients, and may be a useful marker of CV risk in earlier stages of chronic kidney disease (CKD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: 1707 patients with estimated GFR 59 to 30 ml/min per 1.73 m(2) were recruited from primary care practices for the Renal Risk In Derby (RRID) study. Detailed medical history was obtained, and each participant underwent clinical assessment as well as urine and serum biochemistry tests. SAF was assessed (mean of three readings) as a measure of skin AGE deposition using a cutaneous AF device (AGE Reader™, DiagnOptics, Groningen, The Netherlands). RESULTS: Univariate analysis revealed significant correlations between AF readings and several potential risk factors for cardiovascular disease (CVD) and progression of CKD. SAF readings (arbitrary units) were also significantly higher among males (2.8 ± 0.7 versus 2.7 ± 0.6), diabetics (3.0 ± 0.7 versus 2.7 ± 0.6), patients with evidence of self-reported CVD (2.9 ± 0.7 versus 2.7 ± 0.6), and those with no formal educational qualifications (2.8 ± 0.6 versus 2.6 ± 0.6; P < 0.01 for all). Multivariable linear regression analysis identified hemoglobin, diabetes, age, and eGFR as the most significant independent determinants of higher SAF (standardized coefficients -0.16, 0.13, 0.12, and -0.10, respectively; R(2) = 0.17 for equation). CONCLUSION: Increased SAF is independently associated with multiple CV and renal risk factors in CKD 3. Long-term follow-up will assess the value of SAF as a predictor of CV and renal risk in this population.
Authors: Jacques Blacher; Michel E Safar; Alain P Guerin; Bruno Pannier; Sylvain J Marchais; Gérard M London Journal: Kidney Int Date: 2003-05 Impact factor: 10.612
Authors: Sara-Joan Pinto-Sietsma; Gerjan Navis; Wilbert M T Janssen; Dick de Zeeuw; Reinhold O B Gans; Paul E de Jong Journal: Am J Kidney Dis Date: 2003-04 Impact factor: 8.860
Authors: Merlin C Thomas; Con Tsalamandris; Richard MacIsaac; Tanya Medley; Bronwyn Kingwell; Mark E Cooper; George Jerums Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: R Meerwaldt; R Graaff; P H N Oomen; T P Links; J J Jager; N L Alderson; S R Thorpe; J W Baynes; R O B Gans; A J Smit Journal: Diabetologia Date: 2004-07-09 Impact factor: 10.122
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Marjon J Noordzij; Joop D Lefrandt; Erik A H Loeffen; Ben R Saleem; Robbert Meerwaldt; Helen L Lutgers; Andries J Smit; Clark J Zeebregts Journal: Int J Cardiovasc Imaging Date: 2011-02-19 Impact factor: 2.357
Authors: Fabrice Mac-Way; Véronique Couture; Mihai S Utescu; Sophie Ignace; Sacha A De Serres; Renée-Claude Loignon; Karine Marquis; Richard Larivière; Mohsen Agharazii Journal: Int Urol Nephrol Date: 2013-11-17 Impact factor: 2.370
Authors: Malindu E Fernando; Robert G Crowther; Peter A Lazzarini; Kunwarjit S Sangla; Scott Wearing; Petra Buttner; Jonathan Golledge Journal: J Diabetes Sci Technol Date: 2019-06-16
Authors: Michelle John; Tricia M McKeever; Maath Al Haddad; Ian P Hall; Ian Sayers; John R Cockcroft; Charlotte E Bolton Journal: Chron Respir Dis Date: 2016-03-10 Impact factor: 2.444
Authors: Simon D S Fraser; Paul J Roderick; Natasha J McIntyre; Scott Harris; Christopher W McIntyre; Richard J Fluck; Maarten W Taal Journal: Clin J Am Soc Nephrol Date: 2014-05-29 Impact factor: 8.237